[go: up one dir, main page]

FI964124L - Menetelmä kapseloitujen solujen istuttamiseksi isäntään - Google Patents

Menetelmä kapseloitujen solujen istuttamiseksi isäntään Download PDF

Info

Publication number
FI964124L
FI964124L FI964124A FI964124A FI964124L FI 964124 L FI964124 L FI 964124L FI 964124 A FI964124 A FI 964124A FI 964124 A FI964124 A FI 964124A FI 964124 L FI964124 L FI 964124L
Authority
FI
Finland
Prior art keywords
host
encapsulated cells
implanting encapsulated
implanting
cells
Prior art date
Application number
FI964124A
Other languages
English (en)
Swedish (sv)
Other versions
FI964124A0 (fi
FI964124A7 (fi
Inventor
Laura M Holland
Keith E Dionne
Joseph P Hammang
Seth A Rudnick
Michael J Lysaght
Original Assignee
Cytotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytotherapeutics Inc filed Critical Cytotherapeutics Inc
Publication of FI964124A0 publication Critical patent/FI964124A0/fi
Publication of FI964124L publication Critical patent/FI964124L/fi
Publication of FI964124A7 publication Critical patent/FI964124A7/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0613—Cells from endocrine organs
    • C12N5/0614—Adrenal gland
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
FI964124A 1994-04-15 1995-04-13 Menetelmä kapseloitujen solujen istuttamiseksi isäntään FI964124A7 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/228,403 US5550050A (en) 1994-04-15 1994-04-15 Method for implanting encapsulated cells in a host
PCT/US1995/004564 WO1995028166A2 (en) 1994-04-15 1995-04-13 Method for implanting encapsulated cells in a host

Publications (3)

Publication Number Publication Date
FI964124A0 FI964124A0 (fi) 1996-10-14
FI964124L true FI964124L (fi) 1996-10-14
FI964124A7 FI964124A7 (fi) 1996-10-14

Family

ID=22857036

Family Applications (1)

Application Number Title Priority Date Filing Date
FI964124A FI964124A7 (fi) 1994-04-15 1995-04-13 Menetelmä kapseloitujen solujen istuttamiseksi isäntään

Country Status (19)

Country Link
US (1) US5550050A (fi)
EP (2) EP0756487A1 (fi)
JP (2) JPH10501792A (fi)
CN (1) CN1146155A (fi)
AU (1) AU697600B2 (fi)
BR (1) BR9507391A (fi)
CA (1) CA2187335A1 (fi)
CZ (1) CZ300496A3 (fi)
EE (1) EE9600147A (fi)
FI (1) FI964124A7 (fi)
HU (1) HUT75661A (fi)
IL (1) IL113390A0 (fi)
IS (1) IS4368A (fi)
LV (1) LV11730B (fi)
NO (1) NO964358L (fi)
PL (1) PL316845A1 (fi)
SK (1) SK131696A3 (fi)
WO (1) WO1995028166A2 (fi)
ZA (1) ZA953126B (fi)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07503943A (ja) * 1991-10-29 1995-04-27 クローバー　コンソリデイテッド，リミテッド 封入及び薬剤放出に有用な架橋性の多糖類、ポリカチオン及び脂質
US5908623A (en) * 1993-08-12 1999-06-01 Cytotherapeutics, Inc. Compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
US6392118B1 (en) * 1994-07-20 2002-05-21 Neurotech S.A. Mx-1 conditionally immortalized cells
US5935849A (en) * 1994-07-20 1999-08-10 Cytotherapeutics, Inc. Methods and compositions of growth control for cells encapsulated within bioartificial organs
US5620013A (en) * 1994-10-21 1997-04-15 American Cyanamid Company Method for destroying residual lens epithelial cells
US5762925A (en) * 1994-11-03 1998-06-09 Sagen; Jacqueline Preventing opiate tolerance by cellular implantation
US6495364B2 (en) 1995-05-23 2002-12-17 Neurotech, S.A. Mx-1 conditionally immortalized cells
US5855613A (en) 1995-10-13 1999-01-05 Islet Sheet Medical, Inc. Retrievable bioartificial implants having dimensions allowing rapid diffusion of oxygen and rapid biological response to physiological change
EP0888385B1 (en) * 1996-03-14 2003-08-20 Genentech, Inc. Gdnf receptor and uses thereof
US5904144A (en) * 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US6027721A (en) * 1996-05-20 2000-02-22 Cytotherapeutics, Inc. Device and method for encapsulated gene therapy
US6054142A (en) 1996-08-01 2000-04-25 Cyto Therapeutics, Inc. Biocompatible devices with foam scaffolds
US6150164A (en) * 1996-09-30 2000-11-21 The Regents Of The University Of Michigan Methods and compositions of a bioartificial kidney suitable for use in vivo or ex vivo
US6074825A (en) * 1997-07-31 2000-06-13 Maine Medical Center Stable encapsulated reference nucleic acid and method of making
AU9198898A (en) * 1997-09-17 1999-04-05 Alcon Laboratories, Inc. Methods for treating ocular diseases
WO1999013726A1 (en) * 1997-09-19 1999-03-25 University Of South Florida Neuronal cells and an immunosuppressant and anti-inflammatory factor
US6638501B1 (en) 1997-09-29 2003-10-28 Neurospheres Holdings Ltd. Use of multipotent neural stem cell progeny to augment non-neural tissues
US6303136B1 (en) * 1998-04-13 2001-10-16 Neurotech S.A. Cells or tissue attached to a non-degradable filamentous matrix encapsulated by a semi-permeable membrane
US6610540B1 (en) * 1998-11-18 2003-08-26 California Institute Of Technology Low oxygen culturing of central nervous system progenitor cells
US6184035B1 (en) 1998-11-18 2001-02-06 California Institute Of Technology Methods for isolation and activation of, and control of differentiation from, skeletal muscle stem or progenitor cells
US6713293B1 (en) 1999-02-08 2004-03-30 Friedrich Grummt Encapsulated cells containing an amplified expression vector as a drug delivery device
IL138990A0 (en) * 1999-02-12 2001-11-25 Biostream Inc Matrices for drug delivery and methods for making and using the same
US6303355B1 (en) 1999-03-22 2001-10-16 Duke University Method of culturing, cryopreserving and encapsulating pancreatic islet cells
US6365385B1 (en) 1999-03-22 2002-04-02 Duke University Methods of culturing and encapsulating pancreatic islet cells
US20070071734A1 (en) * 1999-04-06 2007-03-29 Weng Tao ARPE-19 as platform cell line for encapsulated cell-based delivery
US6361771B1 (en) 1999-04-06 2002-03-26 Neurotech S.A. ARPE-19 as a platform cell line for encapsulated cell-based delivery
US20050265977A1 (en) * 1999-04-30 2005-12-01 Elliott Robert B Xenotransplant for CNS therapy
US20090047325A1 (en) * 1999-04-30 2009-02-19 Neurotrophincell Pty. Limited Xenotransplant for cns therapy
EP1176970B1 (en) * 1999-04-30 2010-05-19 NeurotrophinCell Pty Ltd Xenotransplant for cns therapy
US20040213768A1 (en) * 1999-04-30 2004-10-28 Elliott Robert Bartlett Preparation for biotransplantation and xenotransplantion and uses thereof
ATE341335T1 (de) * 2000-01-20 2006-10-15 Diabcell Pty Ltd Präparation und xenotransplantation von inseln aus schweinen
US20010031974A1 (en) * 2000-01-31 2001-10-18 Hadlock Theresa A. Neural regeneration conduit
US6719970B1 (en) 2000-07-10 2004-04-13 Alkermes Controlled Therapeutics, Inc. Method of generating cartilage
WO2002032437A1 (en) * 2000-10-17 2002-04-25 Diatranz Limited Preparation and xenotransplantation or porcine islets
US6538010B1 (en) * 2000-11-08 2003-03-25 Research Triangle Institute Compounds and methods for promoting smoking cessation
JP4435563B2 (ja) * 2001-07-10 2010-03-17 バイオジェン アイデック インク アポトーシスプロセスの阻害および細胞性能の改善
EP1281767A3 (en) * 2001-07-31 2003-05-28 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of tumors
US7332330B2 (en) 2001-09-11 2008-02-19 Renamed Biologics, Inc. Device for maintaining vascularization near an implant
WO2003027270A1 (en) * 2001-09-28 2003-04-03 Diabcell Pty Limited Growing xenotransplant material in culture
US20030068308A1 (en) * 2001-10-09 2003-04-10 Jacek Rozga Intrasplenic encapsulated cell therapy
NZ515310A (en) * 2001-11-07 2004-08-27 Diabcell Pty Ltd Methods of treatment and delivery modes
US7442546B2 (en) * 2002-03-15 2008-10-28 The Regents Of The University Of Michigan Method of modulating inflammatory response
EP1369491A1 (en) * 2002-06-05 2003-12-10 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
US20030228261A1 (en) * 2002-06-05 2003-12-11 Aladar Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
AU2002952993A0 (en) 2002-11-29 2002-12-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Therapeutic and diagnostic agents
AU2003901325A0 (en) * 2003-03-21 2003-04-03 Stephen Locarnini Therapeutic, prophylactic and diagnostic agents
US20070043512A1 (en) * 2003-03-26 2007-02-22 Michael Rolph Therapeutic and prophylactic compositions and uses therefor
US7601518B2 (en) 2003-06-10 2009-10-13 Nsgene A/S Secretion of neublastin
SG179291A1 (en) * 2003-06-18 2012-04-27 Genelux Corp Modified recombinant vaccinia viruses and other microorganisms, uses thereof
EP1636346A4 (en) * 2003-06-24 2007-03-28 Diabcell Pty Ltd FROM PIG CULTIVATED PIG ISLE CELLS FOR XENOTRANSPLANTATION
EP1667516A4 (en) 2003-08-29 2009-11-11 Inst Medical W & E Hall METHOD FOR SELECTION OF ANIMAL MODELS FROM ANIMALS MUTAGENICALLY SUBJECTED AND THE USE OF MYB TRANSCRIPTION FACTORS FOR SCREENING
US8066973B2 (en) 2003-09-05 2011-11-29 The Ohio State University Research Foundation Nanoparticulate probe for in vivo monitoring of tissue oxygenation
CA2541385C (en) * 2003-09-05 2013-11-19 The Ohio State University Research Foundation Nanoparticulate probe for in vivo monitoring of tissue oxygenation
MXPA06004329A (es) 2003-10-20 2006-06-05 Nsgene As Terapia genica in vivo de enfermedad de parkinson.
PT1696822E (pt) * 2003-11-13 2010-04-28 Psivida Inc Implante de libertação controlada injectável com um núcleo de matriz biocorrosível e crosta biocorrosível
WO2005068498A2 (en) * 2004-01-19 2005-07-28 Nsgene A/S Human therapeutic cells secreting nerve growth factor
WO2005074923A1 (en) * 2004-02-03 2005-08-18 Agt Biosciences Limited Methods and compositions
ATE430763T1 (de) 2004-03-30 2009-05-15 Nsgene As Therapeutische verwendung des wachstumsfaktors nsg33
NZ551828A (en) 2004-05-12 2009-03-31 Inst Medical W & E Hall A method of cell isolating a homogenous population of mammary stem cells using specific cell surface marker proteins
WO2006013462A2 (en) * 2004-07-30 2006-02-09 Nsgene A/S Growth factors nsg28, nsg30, and nsg32
MX2007012155A (es) * 2005-04-01 2008-04-04 Nsgene As Linea celular precursora neural inmortalizada humana.
NZ563313A (en) * 2005-05-17 2010-01-29 Nsgene As An implantable therapy system for treating a living being with an active factor
NZ540597A (en) * 2005-06-08 2007-02-23 Neurotrophincell Pty Ltd A method for preventing the onset of type I diabetes comprising administering an implantable composition comprising living choroid plexus cells
DK1910535T3 (en) 2005-06-24 2016-09-26 The Walter And Eliza Hall Inst Of Medical Res Therapeutic pro-apoptotic BH-3-like molecules and method of forming and / or selecting the same
CA2627543A1 (en) * 2005-10-28 2007-05-03 Ns Gene A/S Implantable biocompatible immttnoisolatory vehicle for delivery of gdnf
DE102005061801A1 (de) * 2005-12-23 2007-06-28 BSH Bosch und Siemens Hausgeräte GmbH Einschubdosiersystem für Haushaltsgeräte
WO2007078922A2 (en) * 2005-12-30 2007-07-12 Neurotech Usa Inc. Micronized device for the delivery of biologically active molecules and methods of use thereof
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
EP2051726B1 (en) 2006-07-18 2018-04-18 University of Utah Research Foundation Methods for treating pain and screening analgesic compounds
JP5582535B2 (ja) 2007-06-29 2014-09-03 クラレンス ピーティーワイ エルティーディー 点眼投与による神経疾患または精神神経疾患の治療または予防
NZ584848A (en) 2007-09-28 2012-09-28 Intrexon Corp Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
US20090090214A1 (en) * 2007-10-04 2009-04-09 Chung Yuan Christian University Method for forming nano-scale metal particles
US20090196854A1 (en) * 2008-02-04 2009-08-06 Kytos Biosystems S.A. Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery
US20100021437A1 (en) * 2008-04-07 2010-01-28 The McLean Hospital Corporation Whitehead Institute for Biomedical Research Neural stem cells derived from induced pluripotent stem cells
AU2010206374B2 (en) 2009-01-23 2013-01-17 Gloriana Therapeutics Sarl Improved cell lines and their use in encapsulated cell biodelivery
EP2389191A2 (en) 2009-01-23 2011-11-30 NsGene A/S Expression of neuropeptides in mammalian cells
CA2759244A1 (en) * 2009-04-23 2010-10-28 Neurotech Usa, Inc. Cell lines that produce prostaglandin f2 alpha (pgf2a) and uses thereof
FR2948125B1 (fr) 2009-07-17 2011-08-26 Zoran Dermanovic Procedes d'etablissement de symbioses
EP2482828B1 (en) 2009-10-02 2014-12-17 Baxter International Inc Hematopoietic stem cells for use in the treatment of a kidney injury
EP2486128A4 (en) * 2009-10-08 2013-10-09 Neurotech Usa Inc USE OF THE PEDF IN AN ENCAPSULATED CELL DELIVERY SYSTEM
KR101886029B1 (ko) 2010-10-01 2018-08-07 호바 세라퓨틱스 에이피에스 무해자극통증, 통각과민증, 자발통증 및 헛통증의 치료를 위한 메테오린의 용도
ES2613302T3 (es) 2010-12-02 2017-05-23 Neurotech Usa, Inc. Líneas celulares que segregan estructuras de anticuerpos anti-angiogénicas y receptores solubles y usos de los mismos
JP2012215543A (ja) * 2011-03-31 2012-11-08 Sony Corp 個体情報の判定方法、個体情報判定装置、電子機器及び個体情報判定プログラム
WO2013034157A1 (en) 2011-09-05 2013-03-14 Nsgene A/S Treatment of allodynia, hyperalgsia, spontaneous pain, and phantom pain
JP2015508101A (ja) 2012-02-21 2015-03-16 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ Ｃｄ３４＋細胞を含む薬学的組成物
WO2013181424A1 (en) 2012-05-30 2013-12-05 Neurotech Usa, Inc. Cryopreserved implantable cell culture devices and uses thereof
CN116212115A (zh) 2013-03-07 2023-06-06 韦尔赛特公司 三维大容量细胞包封装置组件
CN105377286B (zh) 2013-05-31 2021-07-02 犹他大学研究基金会 芋螺毒素(conotoxin)肽，其医药组合物和用途
US9925219B2 (en) 2013-09-11 2018-03-27 Neurotech Usa, Inc. Encapsulated cell therapy cartridge
EP3662923A1 (en) 2015-05-27 2020-06-10 Neurotech USA, Inc. Use of encapsulated cell therapy for treatment of ophthalmic disorders
US10617738B2 (en) 2015-10-27 2020-04-14 The University Of Queensland Mammalian EphA4 polypeptide derivatives lacking one or more N-glycosylation sites and method of use thereof
WO2022011081A1 (en) 2020-07-09 2022-01-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cell lines that produce human retinoschisin proteins and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352883A (en) * 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4409331A (en) * 1979-03-28 1983-10-11 Damon Corporation Preparation of substances with encapsulated cells
US4298002A (en) * 1979-09-10 1981-11-03 National Patent Development Corporation Porous hydrophilic materials, chambers therefrom, and devices comprising such chambers and biologically active tissue and methods of preparation
US4353888A (en) * 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
NO163060C (no) * 1981-03-13 1990-03-28 Damon Biotech Inc Fremgangsmaate for fremstilling av substanser som dannes av levende celler som produserer interferoner eller antistoffer.
JPS5876086A (ja) * 1981-10-28 1983-05-09 Ajinomoto Co Inc 浮遊性動物細胞の培養法
US4479796A (en) * 1982-11-15 1984-10-30 Medtronic, Inc. Self-regenerating drug administration device
EP0127989A3 (en) * 1983-06-01 1986-03-26 Connaught Laboratories Limited Microencapsulation of living tissue and cells
US4689293A (en) * 1983-06-06 1987-08-25 Connaught Laboratories Limited Microencapsulation of living tissue and cells
US4806355A (en) * 1983-06-06 1989-02-21 Connaught Laboratories Limited Microencapsulation of living tissue and cells
JPS60141286A (ja) * 1983-12-28 1985-07-26 Ajinomoto Co Inc 動物細胞の培養方法および装置
US4749620A (en) * 1984-02-15 1988-06-07 Massachusetts Institute Of Technology Encapsulated active material system
CA1215922A (en) * 1984-05-25 1986-12-30 Connaught Laboratories Limited Microencapsulation of living tissue and cells
GB8500121D0 (en) * 1985-01-03 1985-02-13 Connaught Lab Microencapsulation of living cells
US4868121A (en) 1985-02-07 1989-09-19 Mcdonnell Douglas Corporation Islet isolation process
US4902295A (en) * 1985-08-26 1990-02-20 Hana Biologics, Inc. Transplantable artificial tissue
US4753635A (en) 1986-05-23 1988-06-28 Jacqueline Sagen Inducing analgesia by implantation of cells releasing neuroactive substances
US5026365A (en) * 1987-04-29 1991-06-25 The University Of Massachusetts Method and apparatus for therapeutically treating immunological disorders and disease states
DE3724798A1 (de) * 1987-07-27 1989-02-09 Mengele & Soehne Masch Karl Erntevorsatz an feldhaeckslern
US4942129A (en) * 1987-07-28 1990-07-17 Queen's University At Kingston Multiple membrane microencapsulation
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5106627A (en) * 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5182111A (en) * 1987-11-17 1993-01-26 Boston University Research Foundation In vivo delivery of active factors by co-cultured cell implants
KR0132666B1 (en) * 1989-03-14 1998-04-14 Hitachi Kk Method for controlling cultivation conditions for animal cells
US5002661A (en) * 1989-08-25 1991-03-26 W. R. Grace & Co.-Conn. Artificial pancreatic perfusion device
WO1991009119A1 (en) * 1989-12-13 1991-06-27 Trancel Corporation Improved alginate microcapsules, methods of making and using same
WO1991010470A1 (en) * 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
US5084350A (en) * 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
CA2089582A1 (en) 1990-08-15 1992-02-16 Richard P. Bunge Autotransplantation of schwann cells to promote nervous system repair
EP0585368B1 (en) * 1991-04-25 1997-08-06 Brown University Research Foundation Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
ES2100354T3 (es) 1991-06-28 1997-06-16 Univ Brown Res Found Sistema de implante nervioso.
CA2134088A1 (en) * 1992-04-24 1993-11-11 Robert S. Ward Method of culturing viable cells and method of regulating the level of a compound in a body fluid
CA2140905A1 (en) 1992-07-29 1994-01-30 Keith E. Dionne Use of pouch of implantation of living cells
CA2166116A1 (en) 1993-06-23 1995-01-12 John F. Mills Method and apparatus for sealing implantable, membrane encapsulation devices
ES2178654T3 (es) 1993-08-12 2003-01-01 Neurotech Sa Capsulas biocompatibles inmonoaisladoras que contienen celulas geneticamente alteradas para el suministro de moleculas biologicamente activas.

Also Published As

Publication number Publication date
FI964124A0 (fi) 1996-10-14
EP0756487A1 (en) 1997-02-05
MX9604832A (es) 1998-06-28
NO964358D0 (no) 1996-10-14
CN1146155A (zh) 1997-03-26
JP2005239726A (ja) 2005-09-08
HU9602850D0 (en) 1996-12-30
IL113390A0 (en) 1995-07-31
LV11730A (lv) 1997-04-20
NO964358L (no) 1996-12-13
LV11730B (en) 1998-02-20
CA2187335A1 (en) 1995-10-26
JPH10501792A (ja) 1998-02-17
AU697600B2 (en) 1998-10-08
US5550050A (en) 1996-08-27
IS4368A (is) 1996-10-01
EP1632238A1 (en) 2006-03-08
WO1995028166A3 (en) 1995-11-09
PL316845A1 (en) 1997-02-17
AU2382995A (en) 1995-11-10
HUT75661A (en) 1997-05-28
SK131696A3 (en) 1997-06-04
FI964124A7 (fi) 1996-10-14
ZA953126B (en) 1996-01-04
BR9507391A (pt) 1997-09-16
CZ300496A3 (en) 1997-03-12
EE9600147A (et) 1997-04-15
WO1995028166A2 (en) 1995-10-26

Similar Documents

Publication Publication Date Title
FI964124A7 (fi) Menetelmä kapseloitujen solujen istuttamiseksi isäntään
FI972736A7 (fi) Parannettu menetelmä solun vaihtamiseksi
FI971067L (fi) Menetelmä muistin toteuttamiseksi
FI971065A7 (fi) Menetelmä muistin toteuttamiseksi
BR9607622A (pt) Método para preparar um heteromultímero heteromultímero composição célula hospedeira e método para preparar um heteromultímero
AU8275498A (en) Method for compiling high level programming languages
AU1526095A (en) Method for implanting tissue in a host
FI974139A7 (fi) Menetelmä selluloosan modifioimiseksi
FI971066A7 (fi) Menetelmä muistin toteuttamiseksi
FI19991887L (fi) Menetelmä kalkopyriitin uuttamiseksi
FI971175A7 (fi) Menetelmä polytetrahydrofuraanin valmistamiseksi
FI972262A7 (fi) Menetelmä optisesti aktiivisten metallosenyylifosfiinien valmistamiseksi
FI960145L (fi) Menetelmä sellun valmistamiseksi
FI20050181L (fi) Menetelmä valmistaa 21-kloorikortikosteroideja
FI960752L (fi) Menetelmä tiedonsiirron tehostamiseksi
FI972065L (fi) Menetelmä N-fosfonometyyliglysiinin valmistamiseksi
FI963018L (fi) Menetelmä gammapyronien valmistamiseksi
FI954832L (fi) Uuttomenetelmä
FI955856A0 (fi) Menetelmä sokereiden dekarbonyloimiseksi
FI972694A7 (fi) Uusi menetelmä sameridiinin valmistamiseksi
PH31336A (en) Method for implanting encapsulated cells in a host.
FI944106A0 (fi) Menetelmä hirren valmistamiseksi
GB2292709B (en) Encapsulation method
GB9507029D0 (en) A physical energy development method
FI981251A0 (fi) Menetelmä iso-tiosynnaattien valmistamiseksi